Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia

Infectious Diseases in Clinical Practice

Volumn 7, Issue 5, 1998, Pages 227-233

  Richerson, Mark A ^a,b   Ambrose, Paul G ^b,c   Quintiliani, Richard ^b,d   Bui, Khanh Q ^e   Nightingale, Charles H ^b,e  

^a Dept of Research Administration ^*  (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF THE PACIFIC   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFOTAXIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; ERYTHROMYCIN; GREPAFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ARTICLE; CENTRAL VENOUS CATHETERIZATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION MAKING; DIARRHEA; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL COST; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PNEUMONIA; PRURITUS; TREATMENT FAILURE;

EID: 0031806845     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199806000-00006     Document Type: Article

References (14)

1. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. incidence, etiology, and impact. Am J Med 1985;78:32S-37S.
2. Pachon J, Prado MD, Capote F, et al. Severe community-acquired pneumonia etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142:369-73.
3. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51.179-84.
4. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997;52:17-21.
5. American Thoracic Society, Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148: 1418-26.
6. Niederman MS. Empirical therapy of community-acquired pneumonia. Semin Respir Infect 1994;9:192-8.
7. Bootman JL, Townsend RJ, McGhan WF. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney Books, 1996.
8. Hitt CM, Nightingale CH, Quintiliani R, et al. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. Am J Health Syst Pharm 1997;54:1614-8.
9. Schneider PJ, Gift MG, Lee YP, et al. Cost of medication related problems at a university hospital. Am J Health Syst Pharm 1995;52:2415-8.
10. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA 1995;274:29-34.
11. Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;277:301-6.
12. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1065-72.
13. Concato J, Feinstein AR. Monte Carlo methods in clinical research: application in multivariable analysis. J Invest Med 1997;45:394-400.
14. Gordon GS, Throop D, Berberian L, et al. Validation of the therapeutic recommendations of the American Thoracic Society (ATS) guidelines for community acquired pneumonia in hospitalized patients [abstract]. Chest 1996; 110(Suppl) 55S.